Research programme: phosphatidylcholine-complexed therapeutics - PLx

Drug Profile

Research programme: phosphatidylcholine-complexed therapeutics - PLx

Alternative Names: Indometacin/phosphatidylcholine; Indomethacin-PC; Indomethacin/phosphatidylcholine; Ketorolac/phosphatidylcholine; Meloxicam/phosphatidylcholine; Mesalazine (PL9100 5-ASA); Piroxicam-PC; Piroxicam/phosphatidylcholine; PL 4100; PL 4500; PL 9100 5-ASA

Latest Information Update: 21 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PLx Pharma
  • Class
  • Mechanism of Action Cyclooxygenase inhibitors; Lipoxygenase-cyclooxygenase inhibitors; Prostaglandin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Congenital heart defects
  • Discontinued Gout; Inflammation; Pain; Ulcerative colitis

Most Recent Events

  • 20 Oct 2017 Discontinued - Preclinical for Ulcerative colitis, Pain, Inflammation and Gout (PO), and Pain (IV) in USA (PLx Pharma pipeline, October 2017)
  • 24 Oct 2016 Indomethacin (PL 4100) is still in preclinical development for Congenital-heart-disorders and pain in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Congenital-heart-disorders in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top